The table below shows Crinetics Pharmaceuticals, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$377.92M
-$230.19M
-$168.60M
-$115.20M
-$88.59M
-$62.03M
Capital expenditure
$5.76M
$3.84M
$4.69M
$1.66M
$436.00K
$186.00K
Investing cash flow
$173.91M
-$574.82M
-$200.41M
-$173.98M
-$56.48M
$217.00K
Dividends paid
-
-
-
-
CRNX operating cash flow (10-K history)
Crinetics Pharmaceuticals, Inc. reported operating cash flow of -$377.92M for fiscal year 2025. That is down 64.2% from -$230.19M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$5.47M (FY 2016) to -$377.92M. Figures come from the company's audited annual reports as filed with the SEC.